Major Good News! Zhengqing Haiqin Has Officially Obtained Drug Production License (Certificate B), Ushering in a New Chapter of International Expansion!

A single certificate carries the immense weight of strategic implementation.

Since its establishment in August 2024, Zhengqing Haiqin has been entrusted with the strategic mission of its parent company, Hunan Zhengqing Pharmaceutical Group: to establish itself in the Greater Bay Area as a “new hub for scientific and technological R&D” and a “bridgehead for global expansion.”

The approval of this Class B license not only serves as strong validation of the company’s strategic execution capability, but also marks the transition of the “Three Plus One” strategic layout from blueprint to reality:

Deeply cultivating technological R&D: The company has already engaged in sustained-release formulations, topical transdermal formulations, In-situ gel injectable Comprehensive strategic positioning in cutting-edge areas such as nanocrystal formulations is injecting strong momentum into the company’s future product pipeline.

Deepening Academician Cooperation: By co-building platforms and sharing resources with leading teams of academicians, we are focusing on the development of novel dosage forms and new therapeutic indications, thereby translating scientific expertise into innovative breakthroughs.

Expanding Overseas Operations: Leveraging Hengqin’s unparalleled geographical advantages, we are actively forging pathways for the international expansion of our technologies and products, bringing the dream of globalizing traditional Chinese medicine within reach.

Empowering Technology Transfer: We are not only building momentum for our own growth; we are also incubating new products and greater-health offerings for the Group, driving the efficient translation of innovation resources into value, and fostering synergistic development.

Deeply cultivate the Greater Bay Area and build an international hub of innovation.

A shining achievement of the strategic cooperation between the Huaihua Municipal People’s Government and the Guangdong-Macao Traditional Chinese Medicine Science and Technology Industrial Park. Since its inception, Zhengqing Haiqin has been deeply rooted in the DNA of “openness” and “innovation.”

Locational advantage: close to the water and on the pavilion. The company is located in the picturesque Hengqin, directly across the water from Macao. Situated at the heart of the Guangdong–Hong Kong–Macao Greater Bay Area, it serves as a cutting-edge gateway for connecting global resources. By fully leveraging policy incentives and international resources, we are accelerating the international registration of innovative traditional Chinese medicines and sharing the unique value of TCM with the world.

Co-building the platform and pooling strengths to grow stronger: Backed by the “Hunan Provincial Innovation Center for Technological Advancements in Modern Traditional Chinese Medicine Manufacturing Processes,” the company is continuously strengthening its capabilities across four key areas: resource integration, quality control, R&D innovation, and product development. Currently, the company is concurrently advancing multiple generic drugs and innovative traditional Chinese medicines, while also undertaking the R&D of dozens of Class 1 and Class 2 new drugs within the group, gradually unfolding a grand vision of innovation.

System Upgrade: Safeguarding Quality Across the Entire Lifecycle

Obtaining Certificate B entails a profound responsibility—to ensure the quality of pharmaceutical products throughout their entire lifecycle, from research and development to market launch. To honor this commitment, we spent more than a year building a compliant quality management system from the ground up:

1. Organizational structure, seamless integration: The company has established a comprehensive functional structure covering scientific and technological R&D, manufacturing projects, quality management, pharmacovigilance, and sales development, ensuring that every stage—from the laboratory to the patient—is safeguarded by dedicated expert teams.

2. Compliance System Aligned with International Standards: The company rigorously benchmarks against world-class international standards and has established a comprehensive, science-based management system that covers the entire value chain, including drug registration, on-site inspections, and quality control.

3. New Drug Development: Empowering Through Technology The company focuses on core compounds and boldly integrates cutting-edge technologies such as AI-driven drug discovery to accelerate the design and evaluation of lead compounds, thereby infusing traditional Chinese medicine with a technological soul and propelling its modernization.

Looking Ahead: Co-building a New Glory for Traditional Chinese Medicine

“The issuance of Drug Production License Category B is not the end—it is a new beginning.” We are deeply inspired and acutely aware of the weight of our responsibility.

Looking to the future, Zhengqing Haiqin will steadfastly uphold its two core missions:

Be a practitioner of the modernization of traditional Chinese medicine: Leveraging modern science and technology to unravel the profound therapeutic mechanisms of traditional Chinese medicine, we are committed to developing more first-in-class innovative drugs with significant clinical value, thereby enabling this ancient wisdom to shine brightly within the realm of modern medicine.

Be a pioneer in the international market: Expand into overseas markets and become a pioneer in the global marketplace: Leveraging Hengqin as a strategic hub, we will connect with global markets, align with international standards and resources, and bring “China’s Best Medicines”—borne of Eastern wisdom—to the world.